Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood
暂无分享,去创建一个
J. Tegnér | D. Gómez-Cabrero | R. Kiessling | J. Hansson | Soudabeh Rad Pour | J. Melief | M. Thimma | Yago Pico de Coaña | Maria Wolodarski | Xavier Martinez Demorentin | Manjula Thimma
[1] Andrew J. Wilson,et al. Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer , 2020, BMC cancer.
[2] R. Kiessling,et al. High expression of ID1 in monocytes is strongly associated with phenotypic and functional MDSC markers in advanced melanoma , 2020, Cancer Immunology, Immunotherapy.
[3] R. Kiessling,et al. PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates , 2020, Oncoimmunology.
[4] G. Botti,et al. Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1 , 2019, Journal of Experimental & Clinical Cancer Research.
[5] H. Yao,et al. Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion , 2018, Front. Pharmacol..
[6] Paul Hoffman,et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species , 2018, Nature Biotechnology.
[7] T. Heskes,et al. Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition , 2017, bioRxiv.
[8] C. Billington,et al. Orexin activation counteracts decreases in nonexercise activity thermogenesis (NEAT) caused by high-fat diet , 2017, Physiology & Behavior.
[9] A. Bhardwaj,et al. In situ click chemistry generation of cyclooxygenase-2 inhibitors , 2017, Nature Communications.
[10] R. Kiessling,et al. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma , 2017, Oncotarget.
[11] C. Garbe,et al. Establishing High Dimensional Immune Signatures from Peripheral Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma Patients , 2017, The Journal of Immunology.
[12] P. Wesseling,et al. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function. , 2016, Neuro-oncology.
[13] L. Nardo,et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. , 2016, The Journal of clinical investigation.
[14] Grace X. Y. Zheng,et al. Massively parallel digital transcriptional profiling of single cells , 2016, Nature Communications.
[15] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[16] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[17] J. Wolchok,et al. Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation , 2015, Nature Communications.
[18] F. Cappuzzo,et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.
[19] M. Millenson,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[20] P. Hegde,et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.
[21] P. Stattin,et al. High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome. , 2014, European journal of cancer.
[22] R. Kiessling,et al. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid derived suppressor cells as well as their arginase1 production , 2013, Journal of Translational Medicine.
[23] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[24] S. Wong,et al. Increased Myeloid-Derived Suppressor Cells in Gastric Cancer Correlate with Cancer Stage and Plasma S100A8/A9 Proinflammatory Proteins , 2013, The Journal of Immunology.
[25] Carsten Denkert,et al. Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization , 2012, PloS one.
[26] M. Manns,et al. S100A9 a new marker for monocytic human myeloid‐derived suppressor cells , 2012, Immunology.
[27] B. Carabello. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery , 2011, Current cardiology reports.
[28] D. Foell,et al. Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells1 , 2008, The Journal of Immunology.
[29] W. Nacken,et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein , 2008, The Journal of experimental medicine.
[30] Saeid Ghavami,et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase‐dependent pathway , 2008, Journal of leukocyte biology.
[31] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[32] R. Grobholz,et al. Calcium-Binding Proteins S100A8 and S100A9 as Novel Diagnostic Markers in Human Prostate Cancer , 2005, Clinical Cancer Research.
[33] Y. Benjamini,et al. More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.
[34] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.